ARS Pharmaceuticals Inc (NAS:SPRY)

$ 15.32 0.12 (0.79%) Market Cap: 1.49 Bil Enterprise Value: 1.26 Bil PE Ratio: 0 PB Ratio: 6.90 GF Score: 22/100

ARS Pharmaceuticals Inc at SVB Securities Global Biopharma Conference (Virtual) Transcript
Feb 16, 2023
Silverback Therapeutics Inc and ARS Pharmaceuticals Inc Merger Announcement Call Transcript
Jul 21, 2022
Silverback Therapeutics Inc Strategic Prioritization and Corporate Update Call Transcript
Mar 31, 2022
Silverback Therapeutics Inc at SVB Leerink Global Healthcare (Virtual) Transcript
Feb 16, 2022
Silverback Therapeutics Inc at H C Wainwright Bioconnect Conference (Virtual) Transcript
Jan 10, 2022
Silverback Therapeutics Inc SBT6050 Clinical Data Update Call Transcript
Sep 16, 2021

Silverback Therapeutics Inc SBT6050 Clinical Data Update Call Transcript

Sep 16, 2021 / 10:30AM GMT

Transcript

Operator

Good morning, and welcome to Silverback Therapeutics Investor Event discussing interim data from the SBT-6050-101 clinical study presented at the European Society of Medical Oncology. After the company's prepared remarks, participants will have the opportunity to ask questions. (Operator Instructions)

Please be advised that today's conference may be recorded. (Operator Instructions)

I will now turn over the presentation to Dr. Laura Shawver, CEO of Silverback.

Laura Shawver

Thank you, operator. Good morning, and thanks to everyone for joining us today. We are pleased to discuss the data presented in our ESMO poster from our ongoing Phase I/Ib study of SBT6050 monotherapy and pembrolizumab combination in patients with advanced HER2-expressing or amplified solid tumors. These data are highlighted by enrollment of 40 patients, giving us confidence in the selection of a projected recommended Phase II dose based on safety and tolerability, PK assessments, PD assessments as well as signals of antitumor activity in the heavily pretreated population. .

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.